The FDA has finally approved a long-awaited medication for women with sexual dysfunction. The drug, which has been dubbed “Women’s Viagra,” is scheduled to be released to the public in just one year.

This marks a major milestone in the journey towards gender equality in the realm of sexual health and wellness.

What is Women’s Viagra?

Women’s Viagra, or more formally known as Addyi (flibanserin), is a medication designed to treat hypoactive sexual desire disorder (HSDD) in women.

HSDD is a condition characterized by a lack of sexual desire, which can be stressful and frustrating for those experiencing it. The medicine is designed to increase the levels of neurotransmitters related to sexual arousal and reduce levels of inhibitory chemicals in the brain.

How Does it Work?

Addyi works in a significantly different way than the traditional erectile dysfunction (ED) treatments like Viagra.

Instead of increasing the blood flow to the genital area, it regulates the balance of certain neurotransmitters in the brain which lead to an increase in sexual desire. By taking one pill daily before bedtime, women can experience an increase in libido, which can significantly improve their sexual experience.

Who Can Take It?

Addyi is designed for premenopausal women with diagnosed HSDD, who have not yet experienced a significant reduction in their libido. The drug is not recommended for postmenopausal women nor men.

As a prescription medication, only a healthcare provider can determine if it is suitable for the individual patient.

Side Effects

Like any medication, Addyi has associated risks and side effects. Common side effects may include dizziness, fatigue, nausea, and dry mouth, to name a few.

Additionally, the drug may increase the risk of strong alcohol interaction, so patients are strongly advised not to drink alcohol while taking the treatment.

How Was It Approved?

The FDA has approved Addyi twice, once in 2010 and then again in 2015, but with a recommended Risk Evaluation and Mitigation Strategy (REMS) plan due to its potentially serious side effects.

The approval process has been long and arduous due to the questions surrounding the effectiveness and safety of the medication. Even with the FDA approval, the drug’s development team has faced significant criticism from the medical community regarding the efficacy of the treatment.

The Future of Women’s Health

The approval of Women’s Viagra marks a significant milestone in the evolution of women’s healthcare.

By approving a medication designed to increase sexual desire in women, the FDA has created a major opportunity for women to take control of their sexual health. With further developments and research, it is likely that this product will experience significant improvements and could become a cornerstone medication in the management of HSDD.

What’s Next?

The release of Women’s Viagra is undoubtedly an exciting step forward for women’s healthcare.

It is projected to hit the shelves in just one year from now, which will benefit a vast number of women struggling with sexual dysfunction and HSDD. As we move forward, it is essential that the medical community continues to research and develop more effective remedies and treatments to improve the quality of life for women worldwide.